Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibition.
OBJECTIVE
The C-terminal domain of the soluble epoxide hydrolase (sEH) metabolizes epoxyeicosatrienoic acids (EETs) to their less active diols, while the N-terminal domain demonstrates lipid phosphatase activity. As EETs are potent vasoconstrictors in the pulmonary circulation, we assessed the development of pulmonary hypertension induced by exposure to hypoxia (10% O(2)) for 21 days in wild-type (WT) and sEH(-/-) mice and compared the effects with chronic (4 months) sEH inhibition.


RESULTS
In isolated lungs from WT mice, acute hypoxic vasoconstriction (HPV) was potentiated by sEH inhibition and attenuated by an EET antagonist. After prolonged hypoxia, the acute HPV and sensitivity to the EET antagonist were increased, but potentiation of vasoconstriction following sEH inhibition was not evident. Chronic hypoxia also stimulated the muscularization of pulmonary arteries and decreased sEH expression in WT mice. In normoxic sEH(-/-) mice, acute HPV and small artery muscularization were greater than that in WT lungs and enhanced muscularization was accompanied with decreased voluntary exercise capacity. Acute HPV in sEH(-/-) mice was insensitive to sEH inhibition but inhibited by the EET antagonist and chronic hypoxia induced an exaggerated pulmonary vascular remodelling. In WT mice, chronic sEH inhibition increased serum EET levels but failed to affect acute HPV, right ventricle weight, pulmonary artery muscularization, or voluntary running distance. In human donor lungs, the sEH was expressed in the wall of pulmonary arteries, however, sEH expression was absent in samples from patients with pulmonary hypertension.


CONCLUSIONS
These data suggest that a decrease in sEH expression is intimately linked to pathophysiology of hypoxia-induced pulmonary remodelling and hypertension. However, as sEH inhibitors do not promote the development of pulmonary hypertension it seems likely that the N-terminal lipid phosphatase may play a role in the development of this disease.
Keserü
Benjamin
B
Institute for Vascular Signalling, Johann Wolfgang Goethe University, D-60590 Frankfurt am Main, Germany.
Barbosa-Sicard
Eduardo
E
Schermuly
Ralph T
RT
Tanaka
Hiromasa
H
Hammock
Bruce D
BD
Weissmann
Norbert
N
Fisslthaler
Beate
B
Fleming
Ingrid
I
D000818:Animals; D006332:Cardiomegaly / Q000209:etiology; D004851:Epoxide Hydrolases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000201:enzymology / Q000209:etiology*; D000860:Hypoxia / Q000150:complications* / Q000201:enzymology / Q000503:physiopathology; D051379:Mice; D008810:Mice, Inbred C57BL; D010805:Physical Conditioning, Animal; D011401:Promoter Regions, Genetic; D014661:Vasoconstriction
D004851:Epoxide Hydrolases
Thromb Haemost. 2005 Sep;94(3):630-8
16268482
Am J Physiol Endocrinol Metab. 2009 Aug;297(2):E375-83
19458064
Arch Biochem Biophys. 1993 Aug 15;305(1):197-201
8342951
Prog Lipid Res. 2002 Sep;41(5):369-91
12121718
Mol Pharmacol. 2003 Aug;64(2):482-90
12869654
Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H142-51
17322420
J Biol Chem. 2000 Dec 22;275(51):40504-10
11001943
Circ Res. 2000 Nov 24;87(11):992-8
11090543
Stroke. 2008 May;39(5):1593-6
18323494
J Hypertens. 2009 Feb;27(2):322-31
19226702
Hypertension. 2006 Apr;47(4):762-70
16505204
J Appl Physiol (1985). 2005 Jan;98(1):390-403
15591309
J Biol Chem. 2002 May 3;277(18):15671-6
11867622
Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1558-63
12574510
Am J Physiol Lung Cell Mol Physiol. 2001 Aug;281(2):L314-7
11435204
Resuscitation. 2008 Jan;76(1):89-94
17728042
Proc Natl Acad Sci U S A. 2007 May 22;104(21):9018-23
17495027
Arterioscler Thromb Vasc Biol. 2008 Jun;28(6):1123-9
18340006
J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):13S-24S
15194174
Biochemistry. 2005 Sep 13;44(36):12179-87
16142916
Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1552-7
12574508
Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2186-91
15684051
Hypertension. 2008 Feb;51(2):567-73
18086949
J Cardiovasc Pharmacol. 2005 Dec;46(6):842-8
16306811
J Biol Chem. 2008 Dec 26;283(52):36592-8
18974052
Pediatr Rev. 1999 Nov;20(11):e91-e102
10551895
Hypertension. 2005 Apr;45(4):759-65
15699457
J Cell Sci. 2005 Dec 1;118(Pt 23):5489-98
16291720
Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):42-9
17164131
Respir Physiol Neurobiol. 2004 Jan 15;139(2):191-202
15123002
Biochim Biophys Acta. 2008 Jan;1779(1):17-27
18078836
Biochem Pharmacol. 2002 May 1;63(9):1599-608
12007563
Microvasc Res. 2004 Sep;68(2):75-103
15313118
Biochem J. 2007 Apr 1;403(1):109-18
17112342
FASEB J. 2008 Dec;22(12):4306-15
18725458
Biochem Biophys Res Commun. 2006 Mar 3;341(1):254-60
16414022
J Cardiovasc Pharmacol. 2007 Sep;50(3):225-37
17878749
J Med Chem. 2007 Aug 9;50(16):3825-40
17616115